TY - JOUR
T1 - Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen
AU - Wada, Hisashi
AU - Isobe, Midori
AU - Kakimi, Kazuhiro
AU - Mizote, Yu
AU - Eikawa, Shingo
AU - Sato, Eiichi
AU - Takigawa, Nagio
AU - Kiura, Katsuyuki
AU - Tsuji, Kazuhide
AU - Iwatsuki, Keiji
AU - Yamasaki, Makoto
AU - Miyata, Hiroshi
AU - Matsushita, Hirokazu
AU - Udono, Heiichiro
AU - Seto, Yasuyuki
AU - Yamada, Kazuhiro
AU - Nishikawa, Hiroyoshi
AU - Pan, Linda
AU - Venhaus, Ralph
AU - Oka, Mikio
AU - Doki, Yuichiro
AU - Nakayama, Eiichi
PY - 2014/2
Y1 - 2014/2
N2 - We conducted a clinical trial of an NY-ESO-1 cancer vaccine using 4 synthetic overlapping long peptides (OLP; peptides #1, 79-108; #2, 100-129; #3, 121-150; and #4, 142-173) that include a highly immunogenic region of the NY-ESO-1 molecule. Nine patients were immunized with 0.25 mg each of three 30-mer and a 32-mer long NY-ESO-1 OLP mixed with 0.2 KE Picibanil OK-432 and 1.25 mL Montanide ISA-51. The primary endpoints of this study were safety and NY-ESO-1 immune responses. Five to 18 injections of the NY-ESO-1 OLP vaccine were well tolerated. Vaccine-related adverse events observed were fever and injection site reaction (grade 1 and 2). Two patients showed stable disease after vaccination. An NY-ESO-1-specific humoral immune response was observed in all patients and an antibody against peptide #3 (121-150) was detected firstly and strongly after vaccination. NY-ESO-1 CD4 and CD8 T-cell responses were elicited in these patients and their epitopes were identified. Using a multifunctional cytokine assay, the number of single or double cytokine-producing cells was increased in NY-ESO-1-specific CD4 and CD8 T cells after vaccination. Multiple cytokine-producing cells were observed in PD-1 (-) and PD-1 (+) CD4 T cells. In conclusion, our study indicated that the NY-ESO-1 OLP vaccine mixed with Picibanil OK-432 and Montanide ISA-51 was well tolerated and elicited NY-ESO-1-specific humoral and CD4 and CD8 T-cell responses in immunized patients.
AB - We conducted a clinical trial of an NY-ESO-1 cancer vaccine using 4 synthetic overlapping long peptides (OLP; peptides #1, 79-108; #2, 100-129; #3, 121-150; and #4, 142-173) that include a highly immunogenic region of the NY-ESO-1 molecule. Nine patients were immunized with 0.25 mg each of three 30-mer and a 32-mer long NY-ESO-1 OLP mixed with 0.2 KE Picibanil OK-432 and 1.25 mL Montanide ISA-51. The primary endpoints of this study were safety and NY-ESO-1 immune responses. Five to 18 injections of the NY-ESO-1 OLP vaccine were well tolerated. Vaccine-related adverse events observed were fever and injection site reaction (grade 1 and 2). Two patients showed stable disease after vaccination. An NY-ESO-1-specific humoral immune response was observed in all patients and an antibody against peptide #3 (121-150) was detected firstly and strongly after vaccination. NY-ESO-1 CD4 and CD8 T-cell responses were elicited in these patients and their epitopes were identified. Using a multifunctional cytokine assay, the number of single or double cytokine-producing cells was increased in NY-ESO-1-specific CD4 and CD8 T cells after vaccination. Multiple cytokine-producing cells were observed in PD-1 (-) and PD-1 (+) CD4 T cells. In conclusion, our study indicated that the NY-ESO-1 OLP vaccine mixed with Picibanil OK-432 and Montanide ISA-51 was well tolerated and elicited NY-ESO-1-specific humoral and CD4 and CD8 T-cell responses in immunized patients.
KW - CT antigen
KW - NY-ESO-1
KW - TLR
KW - overlapping peptide vaccine
UR - http://www.scopus.com/inward/record.url?scp=84894484360&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84894484360&partnerID=8YFLogxK
U2 - 10.1097/CJI.0000000000000017
DO - 10.1097/CJI.0000000000000017
M3 - Article
C2 - 24509171
AN - SCOPUS:84894484360
VL - 37
SP - 84
EP - 92
JO - Journal of Biological Response Modifiers
JF - Journal of Biological Response Modifiers
SN - 1524-9557
IS - 2
ER -